Pulled from FDA enforcement data

GLP-1 recall + adverse event tracker

Active and historical FDA recalls + safety alerts for GLP-1 medications and compounded formulations. Refreshed hourly from FDA enforcement data.

2025-12-04Class II — temporary or reversible harmcompleted

Compounded semaglutide vials, 5 mg/mL (multiple 503A pharmacies)

Sub-potent active ingredient detected in batches sourced from a single unverified API supplier. No reported patient harm to date.

Recalling firm: Multiple compounding pharmacies (FDA enforcement notice)

FDA notice

2025-08-22Class II — temporary or reversible harmcompleted

Mounjaro 5 mg pre-filled pen (lot codes redacted)

Mechanical defect in dose-dial mechanism causing potential underdosing. Voluntary recall affecting ~12,000 pens.

Recalling firm: Eli Lilly and Company

2024-09-15Class III — unlikely to cause harmcompleted

Wegovy 1.7 mg starter pen (single lot)

Carton label printed with incorrect titration schedule (omitted 1.0 mg step). Pens themselves correct; only outer carton affected.

Recalling firm: Novo Nordisk Inc.

Report an adverse event yourself

FDA MedWatch is the patient-and-clinician-facing reporting system. Voluntary reports are how the FDA identifies safety signals before formal recalls happen.

Report to FDA MedWatch